Lung cancer is one of the most common diseases in China, and its incidence and mortality rate rank first among all cancers. Immunotherapy drugs represented by PD-1/PD-L1 inhibitors are widely used in clinical practice, and tumor treatment has entered a new era, and more and more tumor patients benefit from immunotherapy. At this stage, the situation of the new crown pneumonia epidemic is grim, in order to better serve the majority of patients, vigorously promote the "Internet +" online service, effectively solve the lung cancer diagnosis and treatment problems encountered in various clinical departments through online discussion, as well as better summarize experience, improve the level of treatment, build an academic platform, and benefit more medical staff and patients, Chengdu High-tech Medical Association successfully held the first to fourth sessions of the "Listening Wendao" lung cancer treatment lecture hall online from March to June 2022.

Due to the needs of epidemic prevention and control, all 4 meetings were held online. The participating experts covered dozens of hospital experts, including West China Hospital of Sichuan University, Peking University Cancer Hospital, Shandong Provincial Cancer Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, The Second Affiliated Hospital of Zhejiang University School of Medicine, Sichuan Provincial People's Hospital and provincial cancer hospitals. All participating experts carried out a stimulating collision of ideas in the form of academic conferences and case sharing.

This conference provides a platform for the exchange of diagnosis and treatment technology and academic scientific research achievements for the majority of clinical doctors and scientific researchers, which is conducive to promoting academic discussions and exchanges of classic cases and cutting-edge technologies of lung cancer, and establishing the concept of comprehensive medical treatment and standardized treatment of lung cancer. It is of great significance to promote high-quality clinical research in the field of medical lung cancer and promote the level of clinical scientific research.